Literature DB >> 24242763

Mesenchymal stem cells ameliorate cerebellar pathology in a mouse model of spinocerebellar ataxia type 1.

Serina Matsuura1, Anton N Shuvaev, Akira Iizuka, Kazuhiro Nakamura, Hirokazu Hirai.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is a progressive neurodegenerative disorder caused by the expansion of a polyglutamine tract in the ataxin-1 protein. To date, no fundamental treatments for SCA1 have been elucidated. However, some studies have shown that mesenchymal stem cells (MSCs) are partially effective in other genetic mouse models of cerebellar ataxia. In this study, we tested the efficacy of the intrathecal injection of MSCs in the treatment of SCA1 in transgenic (SCA1-Tg) mice. We found that intrathecal injection of only 3 × 10(3) MSCs greatly mitigated the cerebellar neuronal disorganization observed in SCA1 transgenic mice (SCA1-Tg mice). Although the Purkinje cells (PCs) of 24-week-old nontreated SCA1-Tg mice displayed a multilayer arrangement, SCA1-Tg mice at a similar age injected with MSCs displayed monolayer PCs. Furthermore, intrathecal injection of MSCs suppressed the atrophy of PC dendrites in SCA1-Tg mice. Finally, behavioral tests demonstrated that MSCs normalized deficits in motor coordination in SCA1-Tg mice. Future studies should be performed to develop optimal protocols for intrathecal transplantation of MSCs in SCA1 model primates with the aim of developing applications for SCA1 patients.

Entities:  

Mesh:

Year:  2014        PMID: 24242763     DOI: 10.1007/s12311-013-0536-1

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  24 in total

Review 1.  Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.

Authors:  Todd Meyerrose; Scott Olson; Suzanne Pontow; Stefanos Kalomoiris; Yunjoon Jung; Geralyn Annett; Gerhard Bauer; Jan A Nolta
Journal:  Adv Drug Deliv Rev       Date:  2010-10-13       Impact factor: 15.470

2.  Isolation of multipotent mesenchymal stem cells from umbilical cord blood.

Authors:  Oscar K Lee; Tom K Kuo; Wei-Ming Chen; Kuan-Der Lee; Shie-Liang Hsieh; Tain-Hsiung Chen
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

3.  Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations.

Authors:  H B Clark; E N Burright; W S Yunis; S Larson; C Wilcox; B Hartman; A Matilla; H Y Zoghbi; H T Orr
Journal:  J Neurosci       Date:  1997-10-01       Impact factor: 6.167

4.  Classification of the hereditary ataxias and paraplegias.

Authors:  A E Harding
Journal:  Lancet       Date:  1983-05-21       Impact factor: 79.321

5.  Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia.

Authors:  Jonathan Jones; Jesús Jaramillo-Merchán; Carlos Bueno; Diego Pastor; Maricarmen Viso-León; Salvador Martínez
Journal:  Neurobiol Dis       Date:  2010-07-15       Impact factor: 5.996

6.  Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells.

Authors:  Jing Liu; Dongmei Han; Zhidong Wang; Mei Xue; Ling Zhu; Hongmin Yan; Xiaoli Zheng; Zikuan Guo; Hengxiang Wang
Journal:  Cytotherapy       Date:  2013-02       Impact factor: 5.414

7.  Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.

Authors:  Mandana Mohyeddin Bonab; Mohammad Ali Sahraian; Aida Aghsaie; Sanaz Ahmadi Karvigh; Seyed Massoud Hosseinian; Behrouz Nikbin; Jamshid Lotfi; Saeideh Khorramnia; Mohammad Reza Motamed; Mansoureh Togha; Mohammad Hossien Harirchian; Nahid Beladi Moghadam; Katayoun Alikhani; Samira Yadegari; Sirous Jafarian; Mohammad Reza Gheini
Journal:  Curr Stem Cell Res Ther       Date:  2012-11       Impact factor: 3.828

8.  SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.

Authors:  E N Burright; H B Clark; A Servadio; T Matilla; R M Feddersen; W S Yunis; L A Duvick; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1995-09-22       Impact factor: 41.582

9.  Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype.

Authors:  Y Robitaille; L Schut; S J Kish
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 10.  Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease.

Authors:  Scott D Olson; Kari Pollock; Amal Kambal; Whitney Cary; Gaela-Marie Mitchell; Jeremy Tempkin; Heather Stewart; Jeannine McGee; Gerhard Bauer; Hyun Sook Kim; Teresa Tempkin; Vicki Wheelock; Geralyn Annett; Gary Dunbar; Jan A Nolta
Journal:  Mol Neurobiol       Date:  2011-12-09       Impact factor: 5.590

View more
  20 in total

1.  Mutant Ataxin-1 Inhibits Neural Progenitor Cell Proliferation in SCA1.

Authors:  Marija Cvetanovic; Yuan-Shih Hu; Puneet Opal
Journal:  Cerebellum       Date:  2017-04       Impact factor: 3.847

Review 2.  Current Perspective of Stem Cell Therapy in Neurodegenerative and Metabolic Diseases.

Authors:  Ajay Kumar; Karthikeyan Narayanan; Ravi Kumar Chaudhary; Sachin Mishra; Sundramurthy Kumar; Kumar Jayaseelan Vinoth; Parasuraman Padmanabhan; Balázs Gulyás
Journal:  Mol Neurobiol       Date:  2016-11-04       Impact factor: 5.590

3.  Transplantation of Embryonic Cerebellar Grafts Improves Gait Parameters in Ataxic Lurcher Mice.

Authors:  Vaclav Babuska; Zbynek Houdek; Jan Tuma; Zdenka Purkartova; Jana Tumova; Milena Kralickova; Frantisek Vozeh; Jan Cendelin
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

4.  Consensus Paper: Strengths and Weaknesses of Animal Models of Spinocerebellar Ataxias and Their Clinical Implications.

Authors:  Jan Cendelin; Marija Cvetanovic; Mandi Gandelman; Hirokazu Hirai; Harry T Orr; Stefan M Pulst; Michael Strupp; Filip Tichanek; Jan Tuma; Mario Manto
Journal:  Cerebellum       Date:  2021-08-10       Impact factor: 3.648

Review 5.  Transplantation and Stem Cell Therapy for Cerebellar Degenerations.

Authors:  Jan Cendelin
Journal:  Cerebellum       Date:  2016-02       Impact factor: 3.847

6.  Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.

Authors:  Catarina Oliveira Miranda; Adriana Marcelo; Teresa Pereira Silva; João Barata; Ana Vasconcelos-Ferreira; Dina Pereira; Clévio Nóbrega; Sónia Duarte; Inês Barros; Joana Alves; José Sereno; Lorena Itatí Petrella; João Castelhano; Vitor Hugo Paiva; Paulo Rodrigues-Santos; Vera Alves; Isabel Nunes-Correia; Rui Jorge Nobre; Célia Gomes; Miguel Castelo-Branco; Luís Pereira de Almeida
Journal:  Mol Ther       Date:  2018-07-12       Impact factor: 11.454

Review 7.  Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases.

Authors:  Faez Siddiqi; John H Wolfe
Journal:  Hum Gene Ther       Date:  2016-07-13       Impact factor: 5.695

Review 8.  Mesenchymal stem cells as a potential therapeutic tool for spinocerebellar ataxia.

Authors:  Kazuhiro Nakamura; Tokue Mieda; Nana Suto; Serina Matsuura; Hirokazu Hirai
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

9.  Cerebellar Differentiation from Human Stem Cells Through Retinoid, Wnt, and Sonic Hedgehog Pathways.

Authors:  Thien Timothy Hua; Julie Bejoy; Liqing Song; Zhe Wang; Ziwei Zeng; Yi Zhou; Yan Li; Qing-Xiang Amy Sang
Journal:  Tissue Eng Part A       Date:  2020-10-01       Impact factor: 4.080

10.  Stem cell models of polyglutamine diseases and their use in cell-based therapies.

Authors:  Evangelia K Siska; George Koliakos; Spyros Petrakis
Journal:  Front Neurosci       Date:  2015-07-14       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.